Akebia Therapeutics names new SVP, CFO and chief business officer
25 June 2024 -

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a United States-based biopharmaceutical company, announced on Monday that it has named Erik Ostrowski as its new senior vice president(SVP), chief financial officer (CFO) and chief business officer.

Ostrowski, an experienced biotech executive with a diverse background across industry leadership roles, board service and investment banking, has served as president, Interim chief executive officer and CFO of Avrobio. He has also served as CFO of Summit Therapeutics and chair of the Audit Committee of the board of directors of Faron Pharmaceuticals. He has served for more than 10 years in investment banking including at Leerink Partners and Robertson Stephens.

John P Butler, Akebia chief executive officer, said, 'We are pleased to welcome Erik to Akebia as he brings proven leadership experience across a broad range of critical functions. He will be an important addition to our experienced leadership team. We are executing the Vafseo (vadadustat) Tablets launch from a solid financial position. Erik's ability to manage all aspects of corporate finance, as well as his track record in leading corporate development and strategic transactions, we believe will enable us to create significant value for our stakeholders.'